相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1986
已完成
1
100.0%
暂无批准数据
- Leading experts at the 2025 Transplant and Cellular Therapy Meetings emphasize the critical need to address social vulnerabilities affecting patient access to stem cell transplants and CAR T-cell therapies. - Dr. Jeff Auletta, senior VP of health equity at National Marrow Donor Program, highlights significant scientific advancements in stem cell transplants and cellular therapies targeting infections and malignant diseases. - Healthcare leaders advocate for systemic changes to improve representation and access for vulnerable populations in advanced cellular therapies, emphasizing the moral responsibility of the medical community.
- Phase 2 ACCESS trial demonstrates 84% one-year overall survival rate using post-transplant cyclophosphamide for GVHD prevention in HLA-mismatched unrelated donor transplants. - Study shows improved GVHD-free, relapse-free survival rate of 48% compared to 38% in previous 15-UUMD trial, marking significant progress in transplant outcomes. - Results indicate successful outcomes regardless of number of HLA mismatches, potentially expanding treatment options for patients requiring stem cell transplantation.
- A new CAST regimen, combining post-transplant cyclophosphamide, abatacept, and tacrolimus, shows promise in preventing graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (HSCT). - The CAST regimen demonstrated a statistically significant reduction in relapse rates and improved disease-free survival compared to the standard GVHD prevention regimen. - The study suggests CAST can improve outcomes in haploidentical HSCT, potentially reducing disparities for patients lacking readily available matched donors. - Researchers advocate for further investigation of the CAST regimen in a randomized controlled trial to confirm its benefits.
